RenovoRx Inc is a medical device company focused on developing innovative solutions for targeted delivery of therapies to treat solid tumor cancers. The company was founded in 2012 by Shaun Bagai and Ramtin Agah, with the vision of advancing cancer treatments through localized drug delivery.
RenovoRx's flagship product is the RenovoCath System, a proprietary medical device designed to deliver therapeutic agents directly to tumor sites within the body. The system combines balloon catheter technology with the ability to infuse chemotherapy and other therapeutic agents directly into the blood supply of solid tumors. This localized delivery approach aims to enhance the efficacy of cancer treatments while minimizing systemic side effects.
The RenovoCath System has been evaluated in clinical trials for various cancer indications, including pancreatic cancer and liver cancer. By enabling targeted delivery of therapies, RenovoRx seeks to improve treatment outcomes and quality of life for patients battling these challenging diseases.
In addition to its clinical development efforts, RenovoRx has been actively engaging in collaborations with leading research institutions and cancer centers to further validate and advance the potential applications of its localized drug delivery technology.